Two small-cap biotech companies with competing CNS-focused pipelines present notably different risk and valuation profiles for investors evaluating behavioral-health innovation.
Volatility and Analyst Outlook
Clearmind Medicine (NASDAQ:CMND) exhibits a beta of 0.64, meaning its stock price is 36% less volatile than the S&P 500. Relmada Therapeutics (NASDAQ:RLMD) shows lower volatility still, with a beta of 0.39, indicating 61% less volatility than the broader market. On analyst sentiment, Relmada holds a consensus target price of $12.00, suggesting potential upside of 90.17%. According to the comparison, analysts view Relmada more favorably than Clearmind based on these metrics.
Ownership Structure
Institutional investors own 96.1% of Clearmind Medicine shares, compared to 45.2% of Relmada Therapeutics shares. Additionally, 14.5% of Relmada shares are held by insiders. The analysis notes that strong institutional ownership typically signals investor confidence in long-term growth potential. Relmada trades at a lower price-to-earnings ratio than Clearmind, positioning it as the more affordable valuation option of the two.
Pipeline and Development Focus
Clearmind Medicine, incorporated in 2017 and based in Vancouver, Canada, develops novel psychedelic medicines targeting alcohol use disorders, mental health conditions, binge drinking, obesity, metabolic disorders, and eating disorders. The company is developing a MEAI compound currently in IND-enabling study for alcohol use disorder treatment and pre-clinical study for obesity and metabolic disorder. Clearmind also collaborates with SciSparc Ltd. on obesity and metabolic syndrome treatment and with Yissum Research Development Company for psychedelic-derived therapeutics addressing mental disorders.
Relmada Therapeutics, headquartered in Coral Gables, Florida, focuses on CNS diseases and related disorders. Its lead candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), an N-methyl-D-aspartate receptor antagonist currently in phase 3 clinical trials for adjunctive or monotherapy treatment of major depressive disorder.
According to the analysis, Relmada beats Clearmind on 8 of the 12 factors compared between the two companies.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.thelincolnianonline.com/2026/06/05/critical-contrast-relmada-therapeutics-nasdaqrlmd-and-clearmind-medicine-nasdaqcmnd.html